Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Trial on the Survival Advantage of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT03986528 is registered in ClinicalTrials.gov with Jie Li as lead sponsor.

NCT NCT03986528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03986528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Trial on the Survival Advantage of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Jie Li
Phase
Phase 4
Overall status
Unknown status
Start date
August 28, 2019
Completion date
May 31, 2022
Enrollment
334 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc